This is a landmark year. On August 22 2019 your Company completes 75 years of itsremarkable existence. On behalf of the entire Board I would like to express my sinceregratitude to all of you our dear shareholders employees and business partners foryour constant support through the decades and for being part of our path-breaking journey.Your trust has been inspirational and instrumental in shaping our success over all theseyears.
This milestone is an occasion to celebrate to reflect on the past and an opportunityto chart the future.
Abbott India is one of the oldest and most respected healthcare companies in India. Itsgrowth trajectory has been sharp with several milestones. The Company incorporates thelegacies of great organizations such as Boots Knoll and then Abbott since 2001. TheCompany'snal position as a global pharmaceutical company with a strong presence in Indiawas enhanced through increased sales better pharmaceutical research and development andsolid commercial grounding. The merger of Solvay Pharma India into the Company provided anexpanded range of healthcare products and a significant impetus to its growth. YourCompany has been steadily achieving its vision of helping people in India live healthierlives through innovative high-quality and trusted products backed by expert clinicalsupport.
Your Company has consistently fulfilled its objectives with significant breakthroughson a long list of strategic initiatives. Today your Company leads from the front inmultiple therapeutic categories such as Women's Health Gastroenterology Metabolics PainManagement Central Nervous System and Vaccines.
As we embark on a new journey we welcome Mr Sudarshan Jain and Mr Mark Murphy II whohave recently joined our Board of Directors. Mr R A Shah who was associated with theCompany for over 35 years retired on March 31 2019 upon completion of his term. Wesincerely thank Mr Shah for his support and guidance and wish him good health and all thebest in the future.
2018 was a year of resilience and successful strategic planning. Total Revenue amountedto र 3792 Crore recording a growth of 10.7% over the previous year. Profits grewby 12.2%. The Company remains on a strong growth trajectory and our motto of"Breaking Barriers Enabling
Care" has been fulfilled in a way that reveals the strengths and capabilities ofthe people behind our success year after year.
In keeping with the solid performance of the Company your Board has proposed adividend of र 50 and special dividend of र 15 per share for the year endedMarch 31 2019.
At Abbott India we don't just break performance barriers we build bridges that showhow much we care. Healthcare Professionals and patients are able to access holistic andquality healthcare solutions through various programs such as "Making India ThyroidAware" in partnership with the Indian Thyroid Society; a 360 degree ecosystemconnecting healthcare professionals and patients; GUTFIT a unique lifestyle modificationprogram and PANCREOSCOPIE an online knowledge sharing platform reaching out toGastroenterologists with cutting-edge insights.
We also seek to create stronger and healthier communities enabling people to fulfiltheir potential and live their life to the fullest. We do so by working with theGovernment international healthcare organizations and community-focused NGOs engagingconsumers and leveraging the skills and passion of our own employees.
The Abbott India team of 3485 dedicated professionals is our most valuable asset.Their commitment and resilience has helped us overcome all challenges in a volatileenvironment. We believe in motivating and engaging our employees through shared goalscapability-building initiatives and career growth opportunities. We provide our peoplewith an environment of transparency accountability and positive reinforcement.
Brand talent and culture remain key factors in delivering sustainable business andearnings growth thus creating long-term value for our stakeholders.
I am proud to announce that your Company was recognised as the "Company of theYear" by AIOCD Pharmasofttech AWACS and received many other prestigious awards forits brands and marketing campaigns.
As we move forward the healthcare landscape in India is expected to improve in thecoming years driven by rising incomes greater health awareness and diagnosis throughtechnology. Government-led initiatives such as Ayushman Bharat and access to insurancewill also help.
We see 2019-20 as another year of consolidation and acceleration. With our Service Plusculture we will ensure differentiation and continue outperforming the market. We willbuild new products to consolidate our leadership in key therapies and enter newhigh-potential areas. We will enhance therapy growth to ensure sustained businessprogress. We will surge ahead with innovative marketing initiatives and services to retainour position as one of the leading pharma companies in India while breaking new ground.
On behalf of our Board of Directors I would once again like to thank you all our shareholders our employees our customers and partners for supporting us on thisexciting journey.